MedWatch

Genmab chief: Morale is sky high

Jan van de Winkel, CEO in Danish antibody company, Genmab, is thrilled with the latest Breakthrough Therapy designation for one of the company’s drugs. It will have a huge effect on how doctors assess the drug, he says.

Foto: Jan van de Winkel, PR

Within less than five months Genmab has won the coveted Breakthrough Therapy designation from the FDA twice. And CEO Jan van de Winkel is clearly thrilled with the development, as Medwatch catches him on the phone immediately following the announcement of the latest Breakthrough designation.

“This is great news. It’s remarkable that it comes so shortly after our first Breakthrough Therapy designation (candidate drug, daratumumab, won the designation on May 1, 2013, ed.). It is very rare to see a company with two Breakthrough designations for two different drugs. But the important thing is that it will make it easier to advance Arzerra,” the CEO says in an interview with Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier